CTRI/2018/04/013334招募中4 期
A randomized, double blind, placebo-controlled, study to evaluate the effectiveness of plant extract based natural oils MJR(F), Yin(PC) and Endobal abdominal massage in management of Polycystic Ovarian Syndrome (PCOS) - PCOS
Gods Own Store0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Married Female patients of age group 18-40 years diagnosed with polycystic ovarian syndrome/disease (PCOS or PCOD) and suffering from primary infertility, irregular/scanty menses due to anovulatory cycles and increased LH levels in blood will be included in the study.
- •2.LH: FSH ratio > 3 confirmed by hematological examinations, will be enrolled in the study.
- •3.Subjects with clinical or biochemical evidence of Hyperandrogenism will be included.
- •4.Subjects must have a negative pregnancy test. Pregnant patients and lactating mothers will be excluded from the study.
- •5.Participants should be willing to sign a written consent for participation in the study and undergo a baseline interview.
- •6.Participants must be willing to commit to medication dosing and assessment visits for evaluation.
- •7.Participants must be willing to refrain from taking any other medications for treatment of PCOD, irregular menses and infertility including HRT from the outset of the study until final evaluation (if patient force to take above said medicine, subject will be dropped from the study).
- •8.Participants must agree that during the study they will refrain from taking any new herbal supplement and prescription or nonprescription medications without prior approval of the research team.
- •9.Participants must agree to take healthy diet and life style.
排除标准
- •1.Unmarried subjects,
- •2. subjects who are pregnant or lactating mothers.
- •3.Patients currently on HRT or having taken any herbal medications in the last 30 days will be excluded from the study.
- •4.Patients diagnosed with cervical tumor, polyp or cervical cancer
- •5.Patient diagnosed with uterine fibroid, congenital anomalies in female genital tract, tubercular endometritis, congenital adrenal hyperplasia.
- •6.Patients that are HIV/VDRL/HbsAg positive.
- •7.Participants with evidence or history of significant systemic, immunological, gynaecological disorder. (People with hypothyroidism who are on adequate and stable thyroid replacement will not be excluded).
- •8.Any participant who is not able to give adequate informed consent.
研究者
相似试验
进行中(未招募)
1 期
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular DystrophyDuchenne Muscular DystrophyEUCTR2016-001654-18-SEF. Hoffmann-La Roche Ltd159
进行中(未招募)
1 期
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular DystrophyDuchenne Muscular DystrophyMedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2016-001654-18-DEF. Hoffmann-La Roche Ltd159
进行中(未招募)
1 期
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 (BMS-986089) in Ambulatory Boys With Duchenne Muscular DystrophyDuchenne Muscular DystrophyMedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2016-001654-18-BEF. Hoffmann-La Roche Ltd159
招募中
2 期
Clinical study on gastrointestinal health.CTRI/2022/01/039174Mr Kamlesh Thummar
进行中(未招募)
1 期
Investigating otilimab in patients with severe coronavirus related lung disease.Severe pulmonary COVID-19 related diseaseMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862EUCTR2020-001759-42-BEGlaxoSmithKline Research & Development Limited1,150
